It was also reported that combinatorial therapy with pan-RAF inhibitors and YAP inhibitor had synergistic effects on KRAS-mutant pancreatic cancer (16); on the other hand, the antitumor activity of verteporfin in colon cancer was demonstrated to be independent of YAP (17). This evidence concerns the gene YAP1 and familial pancreatic carcinoma.